Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Total Debt: 2023-2025

Historic Total Debt for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to $11.2 million.

  • BioLineRx's Total Debt fell 61.97% to $11.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $11.2 million, marking a year-over-year decrease of 61.97%. This contributed to the annual value of $13.4 million for FY2024, which is 37.49% up from last year.
  • According to the latest figures from Q2 2025, BioLineRx's Total Debt is $11.2 million, which was down 9.09% from $12.3 million recorded in Q1 2025.
  • Over the past 5 years, BioLineRx's Total Debt peaked at $29.4 million during Q2 2024, and registered a low of $9.6 million during Q1 2024.
  • Over the past 3 years, BioLineRx's median Total Debt value was $11.6 million (recorded in 2023), while the average stood at $14.7 million.
  • Per our database at Business Quant, BioLineRx's Total Debt skyrocketed by 154.44% in 2024 and then crashed by 61.97% in 2025.
  • Over the past 3 years, BioLineRx's Total Debt (Quarterly) stood at $9.8 million in 2023, then soared by 37.49% to $13.4 million in 2024, then tumbled by 61.97% to $11.2 million in 2025.
  • Its last three reported values are $11.2 million in Q2 2025, $12.3 million for Q1 2025, and $13.4 million during Q4 2024.